Fredrik Lindgren appointed new President and CEO of Hansa Medical

The Board of Directors of Hansa Medical has appointed Fredrik Lindgren to CEO. Fredrik Lindgren is a member of the board of Hansa Medical since 2012 and takes up the position as CEO with immediate effect. Fredrik Lindgren replaces Emanuel Björne who remains with the company in a commercial position.

"Hansa Medical has made significant progress during the last period of time. We are now in a very exiting position with phase II trials of IdeS. This means that we need new competencies for the further development and commercialization of IdeS. Emanuel Björne has achieved a lot during his seven years as CEO and we are truly grateful for his efforts. Fredrik Lindgren now assumes the main responsibility for completing the development of IdeS to create a large and profitable business for Hansa Medical’s shareholders." says Birgit Stattin Norinder, Chairman of the Board.

Fredrik Lindgren, born 1971, has significant experience from the life science sector and has led several public companies. He has been CEO of Karo Bio AB and Biolin Scientific AB, and has executive experience from Midsona AB and Active Biotech AB. Fredrik Lindgren has a law degree from Lund University and is CEFA from Stockholm School of Economics. Fredrik Lindgren owns 23 333 shares in Hansa Medical. He is currently a member of the board of ProstaLund AB and Exini Diagnostics AB. Upon assuming the position as CEO, Fredrik Lindgren will resign from the position as member of the board of Hansa Medical.

For additional information, please contact:

Birgit Stattin Norinder, chairman of the board
E-mail: birgitsn@telia.com
Mobile: +46 706 62 61 80

Fredrik Lindgren, appointed CEO
Mobile: +46 705 61 61 77


Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory conditions. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.

About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.